The detection of pretreatment ABL1 mutations is therefore unlikely to meaningfully guide upfront treatment decisions (e.g., TKI selection) in patients with newly diagnosed Ph + ALL. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.